Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs W W Grainger Inc (GWW) Price & Performance

Abeona Therapeutics IncTrade
W W Grainger IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs W W Grainger Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while W W Grainger Inc trades at $1,305.49 (market cap $61.32B). The key difference: W W Grainger Inc is far larger — about 145.6× Abeona Therapeutics Inc's market cap, and W W Grainger Inc pays a 0.77% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEOGWW
Market Cap
$421.19M$61.32B
Sector
HealthTechnology
52-Week High
$7.45$1.40K
52-Week Low
$4.17$918.18
Enterprise Value
$276.10M$63.53B
Dividend Yield
0.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.

Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.

W W Grainger Inc

W.W. Grainger (GWW) trades at $1,304.88, up 0.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 results, beating EPS and revenue estimates, and raised its full-year outlook. Revenue grew to $18.8 billion in 2026, with a net income margin of 9.92%. Analyst consensus is a 'Hold' with a $1,320 price target, though institutional sentiment is mixed amid high valuation multiples.

GWW's earnings momentum and market share gains support upside potential, but elevated P/E of 33.19 and bearish technicals pose near-term risks. Investors should weigh robust fundamentals against valuation concerns and macroeconomic pressures affecting industrial demand.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About W W Grainger Inc

Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.

Read more on GWW